Company ProfilePremium

Aayush Wellness Limited (formerly Aayush Food and Herbs Limited)

Company Profile Analysis

Tickers: AAYUSH.NS, 539528.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aayush Wellness Limited - Company showcase

Year Founded & Workforce

1984

Aayush Wellness Limited logo

Aayush Wellness Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aayush Wellness Limited Overview

Aayush Wellness Limited is a BSE/MSEI-listed Indian micro-cap. Since 2023–24 it has repositioned itself from a dormant rice-trading shell, the former Aayush Food and Herbs Limited, into what management calls an "integrated healthcare and preventive wellness company". Its revenue base was effectively nil in FY2024. It reached ₹73 crore in FY2025 and ₹155 crore in FY2026, and stood at ₹166 crore on a trailing basis by June 2026. Operating margins, however, are only 1–2%, a profile closer to distribution or trading than to branded consumer health. The product portfolio is herbal and nutraceutical: herbal pan masala, gummies, and condition-specific Ayurvedic tablets for immunity, liver, diabetes, lung and calcium. Around it, the company has layered stated ambitions in diagnostics (Aayush Labs), smart health kiosks, tele-consultation, wellness tourism and Southeast Asian exports through a Singapore subsidiary. The company has no promoter, a concentrated non-institutional shareholder base, and has changed auditors repeatedly. The equity has fallen about 90% from its July 2025 peak.


The company's own description

The company's recent filings and press releases describe Aayush Wellness as an integrated healthcare company. They say it focuses on preventive healthcare, nutraceuticals, wellness supplements and condition-specific healthcare products, and that it is building a "scalable healthcare and wellness ecosystem". The company also says it holds ISO 9000 and ISO 22000 certifications. The FY2023–24 Annual Report presents a vision of a "healthier, happier India" with products that "bridge nutritional gaps". Screener's summary of the FY2024 Annual Report says the company describes an integrated platform offering online doctor consultations, nutritional support programmes and health-awareness campaigns. Third-party profiles (S&P Global via Simply Wall St) describe a business spanning development, production, marketing and distribution of health and wellness products under the "Aayush" brand.

Earlier self-descriptions are materially different, and the change is important context:

FY2016–FY2023 (Aayush Food and Herbs): a trader of basmati and non-basmati rice, selling in India and exporting, mainly to the Gulf and West Africa. Rice trading and export began in the last quarter of FY2015–16.

Late 2024: "India's smart nutrition company" (November 2024 and January 2025 press releases).

2025–2026: "integrated healthcare company" and "preventive healthcare company".

Independent characterisation

Judged by its financial statements, Aayush Wellness is today a low-margin consumer health and nutraceutical trading and distribution business with an aspirational healthcare-services layer:

  1. Revenue scale vs. margin profile. FY2026 consolidated revenue was ₹155.5 crore against operating profit (EBITDA) of only about ₹1.8 crore, an operating margin of about 1.2%. TTM gross profit is reported at about ₹5.4 crore (₹54.0 million) on ₹170 crore revenue (Simply Wall St, S&P data), a gross margin of about 3%. Branded nutraceutical companies typically report gross margins of 40–70%. A 3% gross margin points to traded or contract-manufactured volume, or institutional and export bulk sales, rather than branded retail at full margin.

  2. Working-capital profile. Debtor days are about 0, inventory days about 2 and payable days about 1 (Screener, FY2026). This is unusual for an FMCG or nutraceutical brand, which would normally carry channel receivables and inventory. It looks more like back-to-back trading.

  3. Asset-light. Fixed assets are effectively zero (rounded to ₹0 crore in FY2024–FY2026) and depreciation is ₹0.01 crore per quarter. No owned manufacturing plant is disclosed. Products are presumably made by third-party (loan-licence or contract) manufacturers. This is not confirmed in filings reviewed.

  4. Earnings composition. In FY2026, other income of about ₹2.6 crore (₹0.65 crore in each of the four quarters, and again in Q1 FY2027) made up roughly 59% of profit before tax (about ₹4.4 crore). The core operating business contributed only about ₹1.8 crore.

Business model and revenue model

Revenue streamModelDisclosure status
Branded herbal/nutraceutical products (pan masala, gummies, tablets, capsules)Product sales, B2C via e-commerce (own online platform, Flipkart, Blinkit) and offline distributionLaunched; revenue split not disclosed
Export of nutraceuticals (Singapore: effervescent tablets, marine collagen, probiotics, super-greens powders)B2B product supply to distributor (Cosmos Holdings Pte Ltd)US$3 million order announced Dec 2024, deliverable over about 12 months; recognised revenue not disclosed
Healthcare services: Aayush Health Centre (Virar), Smart Health ATMs/kiosks, tele-consultation, diagnostics (Aayush Labs), genome testingService and fee-based; intended recurring revenueAnnounced 2025; revenue contribution not disclosed, likely immaterial
Wellness tourism (retreats)Service/experienceAnnounced Dec 2024; no evidence of operating revenue
Startup accelerator / investment corpus (₹5 crore)Strategic investmentAnnounced 2025; Healthrashi collaboration is the only named deal

Product vs. service vs. subscription vs. licensing mix: not publicly disclosed. Based on the margin and asset profile, product sales almost certainly account for all or nearly all revenue. There is no evidence of subscription or licensing revenue.

Value-chain position

Aayush sits in the brand-owner / marketer / distributor layer. It outsources formulation manufacturing (inferred from negligible fixed assets), and sells through third-party digital marketplaces, quick commerce and export distributors. It does not appear to own raw-material sourcing, manufacturing, or retail infrastructure, apart from the single Virar health centre.

Customer types and end-markets

Customer typeEnd-market
Urban retail consumers (e-commerce, quick commerce)Indian nutraceuticals / dietary supplements; herbal mouth fresheners (pan masala substitute)
Export distributorsSingapore / ASEAN health supplements
Patients and local communities (Virar health centre, kiosks)Primary preventive care, diagnostics, tele-medicine
Government health programmes (stated intention)Public preventive health (e-Sanjeevani-style telemedicine)

Strategy

Stated strategy themes (paraphrased from FY2024–FY2026 filings and press releases)

  1. Preventive healthcare positioning. The company aims to be an integrated preventive-healthcare and wellness platform rather than a single-product company.

  2. Portfolio breadth in condition-specific nutraceuticals. It is launching roughly one new SKU every 1–3 months across sleep, beauty, cognition, immunity, liver, metabolic, respiratory and bone health.

  3. Omnichannel distribution. Own D2C platform, marketplaces (Flipkart), quick commerce (Blinkit), offline, and exports.

  4. Healthcare services and digital health. Smart health kiosks, the Virar health centre, tele-consultation, diagnostics (Aayush Labs) and genome testing.

  5. Internationalisation. Singapore hub for ASEAN and the export subsidiary in India.

  6. Ecosystem investing. A ₹5 crore startup accelerator / investment corpus.

  7. Ayurveda-plus-science branding. Ancient Ayurvedic principles combined with modern formulation.

Initiative register (last 24 months)

DateInitiativeTypeQuantified targetStatus
Jul 2024Online platformChannel—Live
Jun 2024ESOP 2024TalentPool size not capturedGrants approved 7 Jan 2026
Dec 2024Wellness tourismNew business—No evidence of execution
Early 2025₹5 crore (₹50 million) startup/investment corpusInvestment₹5 croreOne collaboration (Healthrashi)
Apr 2025Diagnostics via genome testingNew business—Aayush Labs launched Sep 2025
Apr 2025Virar health centre / Smart Health ATMServicesNational roll-outOne site disclosed
Jun 2025Smart Health Kiosks and Medical Support CentresCapex planUp to ₹25 crore initial phaseNo capex visible in FY2026 cash flow (capex ≈ 0)
Jun–Sep 2025Singapore subsidiaryInternationalSGD 10,000 seedIncorporated
Sep 2025Healthrashi collaborationPartnership / sourcing—Signed
Nov 2025Blinkit partnershipChannel—Live
Dec 2025 – Oct 2026Five new tablet launchesProduct—Launched
Jun 2026Herbal masala push in Maharashtra post-MCOCA gutkha crackdownMarket opportunity—Messaging only

ESG commitments

None disclosed.

Cost programmes

None disclosed.

Medium-term guidance

Not publicly disclosed. No revenue, margin or EPS guidance was found. The ScanX coverage of Q1 FY2027 explicitly notes the absence of management guidance. Third-party commentary (Sahi, Aug 2026) lists OPM sustainably above 5% and net margin above 4.5% as monitorables. These are analyst framings, not company targets.

Analyst observation. The ₹25 crore kiosk plan is about twice the company's FY2026 net worth (about ₹12 crore). FY2026 cash flows show no capex and only about ₹5 crore of new borrowings. Funding for the stated healthcare-services ambitions is therefore unclear, and execution should be presumed slow or partial until capex appears in reported cash flows.

Products & Services

Consumer products (branded "Aayush")

#ProductLaunch dateDescription / key ingredients (as disclosed)Target customerPricing
1Aayush Herbal Pan MasalaJun 2024 (BSE intimation); listed on Flipkart (2024)Herbal mouth freshener positioned as a tobacco-free, Ayurveda-inspired alternative to gutkha/pan masala; company links it to "tobacco de-addiction"Adult consumers of mouth fresheners / pan masala, especially in Maharashtra (company press release, Jun 2026)—
2Dreamy Sleep GummiesFY2025Gummy supplement to support sleep and relaxationUrban adults with sleep issues—
3Beauty Vitamin GummiesFY2025Gummy supplement for skin, hair and nailsUrban adults (beauty-from-within)—
4Brain Fuel Capsules11 Jul 2025Herbal cognitive-support blend: Brahmi (Bacopa monnieri), Ashwagandha, Ginkgo biloba, Turmeric/curcumin, Gotu Kola (Centella asiatica)Students, professionals, elderly—
5Immunity Booster Tablets8 Dec 2025Blend of traditional and science-backed ingredients to support the body's natural defences (formula not itemised in sources)General population; seasonal demand—
6Liver Care / Liver Detox Tablets24 Apr 2026Herbal formulation for liver detoxification, protection and regenerationLifestyle-disease-affected adults—
7Aayush Dia Shield Tablets8 May 2026Preventive/supportive product for long-term blood-sugar management; company frames entry into a ₹366.56 billion metabolic-health marketPre-diabetic / diabetic adults—
8Lung Care Tablets29 Aug 2026Respiratory-wellness formulation; company cites an ₹18,913 crore respiratory marketUrban adults exposed to pollution; respiratory wellness—
9Aayush Calcium Vitamin Tablets16 Oct 2026Calcium and vitamin supplement (bone health)Women, elderly, general—

Export / B2B nutraceutical lines (Cosmos Holdings order, Dec 2024)

The company's disclosure names four categories: effervescent tablets, marine collagen, probiotics, and super-greens powders ("and more"). Delivery was to run over about one year. Branding (Aayush vs. private label) is not disclosed.

Healthcare services

#ServiceLaunchDescriptionStatus
1Online health/wellness platform3 Jul 2024E-commerce and digital access to products; online doctor consultations, nutrition programmes (per FY2024 AR summary)Operating
2Aayush Health Centre, Virar (Mumbai) with Smart Health ATM ("Cloud Clinic")26 Apr 2025Kiosk-based quick diagnostics and telemedicine, modelled on the Health Ministry's e-Sanjeevani service; also mental-wellness programmesOne centre disclosed; national scale-up planned
3Smart Health Kiosks & Medical Support CentresPlan announced Jun 2025Up to ₹25 crore investment in the initial phaseExecution status not disclosed
4Genome-testing-led diagnosticsAnnounced 15 Apr 2025Entry into diagnostics via genome testingStatus not disclosed
5Tele-consultation and diagnostic testingAnnounced 21 Jun 2025Foray into tele-medicine and diagnosticsStatus not disclosed
6Aayush Labs3 Sep 2025Diagnostics brand positioned as accessible, affordable and patient-firstLaunched; revenue not disclosed
7Healthrashi-sourced equipment (AI health kiosks, mobile clinics, automated diagnostic platforms, healthcare vending machines)22–23 Sep 2025Deployed under Aayush's own brandStatus not disclosed
8Wellness tourism retreatsAnnounced 23 Dec 2024Retreats with nutritional counselling, workshops and Ayurveda therapies; partnerships with tourism boards contemplatedNo operating evidence

Distribution channels

Own e-commerce site (Jul 2024), Flipkart (pan masala), Blinkit quick commerce (Nov 2025), offline distribution (not detailed), export distributor (Cosmos Holdings Pte Ltd, Singapore).

Financial Narrative

Income statement (INR crore)

Sources and reconciliation:

  • FY2022–FY2023 revenue, expenses and operating profit come from the Screener standalone history (BSE data). PAT for these years is not reliably extractable from the sources reviewed. Screener showed negative ROE (about -9% to -12%) for the period, implying losses.

  • FY2024 is Screener consolidated: sales ₹0.60 crore, OPM 58%, PAT ₹0.57 crore, EPS ₹0.12. Angel One cites FY2024 revenue of ₹0.84 crore (probably total income) and EPS of ₹0.176 (probably not bonus-adjusted). Both are noted.

  • FY2025 revenue of ₹73.39 crore and PAT of ₹3.37 crore are from Angel One's coverage of the FY2025 results. Business Guardian (Jun 2025) cites income from operations of ₹73.34 crore and net profit of ₹3.05 crore (+434%), possibly standalone or a different line. Quarterly consolidated PAT sums to ₹3.35 crore. FY2025 EBITDA is the sum of quarterly operating profit (0.24 + 0.92 + 1.09 + 1.19); Screener's annual OPM is 4.5%.

  • FY2026 revenue from operations of ₹155.48 crore (+112%) is from the company press release (Tribune/ANI, 2 Jun 2026). EBITDA, other income, PBT and PAT are sums of the four FY2026 quarters on Screener (EBITDA 0.51 + 0.56 + 0.41 + 0.35; other income 0.65 × 4; PBT 1.15 + 1.20 + 1.05 + 0.99; PAT 1.16 + 1.21 + 1.05 + 0.56). Annual EPS is ₹0.82.

  • The FY2025 dividend was an interim of ₹0.01 per share. The ₹0.025 per share appears in the FY2025 Directors' Report and is consistent with Screener's 3% FY2026 payout. Timing of declaration (final FY2025 vs. FY2026) should be confirmed against the FY2026 Annual Report.

Margin analysis (%)

The FY2026 gross margin is a TTM proxy: Simply Wall St (S&P) gross profit of ₹54.0 million on revenue of ₹1.7 billion. Annual gross profit is not separately disclosed in the sources reviewed. FY2024 margins are meaningless because the revenue base was only ₹0.6 crore.

Growth

5-year revenue CAGR (FY2021 to FY2026): FY2021 standalone revenue was ₹151.58 crore (rice trading) and FY2026 was ₹155.48 crore. The CAGR is about 0.5%. After a near-total collapse and rebuild, the company's revenue is only now back to its FY2021 level.

2-year CAGR (FY2024 to FY2026): about 1,510% p.a. This is mathematically correct but analytically meaningless given the base.

Quarterly trend (consolidated, INR crore)

Source: Screener.in consolidated quarterly results (BSE filings). Business Standard reports a Q1 FY2027 OPM of 2.36% against Screener's 2.33%.

Key reading of the quarterly data:

  1. Margin compression as revenue scaled. OPM peaked at 6.4% in Q2 FY2025 and fell steadily to 0.7% by Q4 FY2026, even as quarterly revenue more than tripled. That is the opposite of the operating leverage expected from a brand-building business. It suggests incremental revenue came from very low-margin traded or bulk volume.

  2. Other income propped up profit. From Q1 FY2026 a constant ₹0.65 crore per quarter appeared and kept PBT flat at about ₹1.0–1.2 crore while core operating profit halved. The source of this income (interest on inter-corporate deposits, treasury income, or other) is not disclosed in the sources reviewed and is a priority diligence item. Screener flags that earnings include ₹2.60 crore of other income and that the company "might be capitalising interest cost".

  3. Q4 FY2026 tax charge. An effective tax rate of 43% cut Q4 PAT to ₹0.56 crore (down 49% YoY). The rate was about 0% in the other quarters (low tax rate flagged by Screener). That suggests a catch-up provision or the use of carry-forward losses.

  4. Q1 FY2027 sequential decline. Revenue fell 32% QoQ (₹48.4 crore to ₹33.1 crore) even though it grew 46% YoY. This breaks the sequential growth run of FY2026.

Balance sheet (consolidated, INR crore; FY2022–FY2023 standalone where available)

Source: Screener consolidated balance sheet (rounded to nearest crore). Book value per share is ₹2.52 (Oct 2026), so FY2026 equity is about ₹12.3 crore.

Short-term vs. long-term debt split: not disclosed in the sources reviewed. MarketInOut reports debt/equity of 0.39 (consistent with about ₹5 crore of borrowings on about ₹12 crore of equity).

Cash and equivalents / net debt: not disclosed in the sources reviewed. FY2026 net cash flow was about +₹2 crore, so cash is likely low single-digit crore.

Working capital: Screener working-capital days were about 0 in FY2026 (268 in FY2024, 3 in FY2025).

Capital raising: paid-up capital rose from about ₹3 crore to about ₹5 crore between FY2024 and FY2025, mainly from the 1:2 bonus (capitalised from reserves) after the split. A planned rights issue (promoter named by IPO Central as Pallavi Mittal) was reported in Dec 2024. No completed rights issue was found.

Cash flow (consolidated, INR crore)

Source: Screener consolidated cash flows. Dividends paid round to ₹0 crore (₹0.01 per share × 4.87 crore shares ≈ ₹0.05 crore).

  • In FY2026, borrowings rose by about ₹5 crore but financing cash flow rounds to ₹0. The rounding or classification should be checked against the audited cash-flow statement in the FY2026 Annual Report.

  • Cumulative FY2024–FY2026 operating cash flow was negative while cumulative reported PAT was about ₹7.9 crore. Earnings are not converting to cash.

Key ratios

Sources: Screener ratios (ROCE, debtor/inventory/payable days, CCC; ROE latest 38.8%; 3-year average ROE 36.4%). MarketInOut TTM as of Jul 2026 (ROA 28.20, ROIC 13.19, ROE 38.29, interest cover 277, D/E 0.39). Asset turnover is computed as revenue ÷ total assets. The current ratio is not disclosed. Net debt/EBITDA cannot be computed without a cash figure.

Commentary. The high ROE and ROCE are arithmetic results of a tiny equity base (about ₹12 crore) and of other income. They do not show a strong franchise. Strip out other income and FY2026 core pre-tax return on equity falls to roughly 15%. The asset-turnover ratio of about 8.6x is typical of commodity trading, not of nutraceutical brand-building.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business line (implied)ContentsRevenue 3-yrStatus

Wellness and nutraceutical products

Pan masala, gummies, tablets, capsules

—

Operating

Exports

Singapore nutraceutical supply (Cosmos order) via parent / Aayush Worldwide / Aayush International

—

Operating (order-based)

Healthcare services

Health centre, kiosks, tele-consult, diagnostics (Aayush Labs)

—

Early stage

Wellness tourism

Retreats

Nil evident

Announced only

“—” = not publicly disclosed.

Revenue by Segment

Metric (INR Cr)Q1FY2026Q1FY2027

Consolidated revenue from operations

22.6333.11

Standalone revenue from operations

22.6324.72

Implied subsidiary revenue

08.39

Consolidated PAT

1.161.42

Standalone PAT

1.161.20

Implied subsidiary PAT

00.22

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityRelationshipJurisdictionIncorporatedStated purpose

Aayush Wellness Limited

Listed parent

India (Maharashtra since Dec 2025)

1984

Holding / operating company

Aayush Healthsciences Private Limited

WOS

India

7 Nov 2024

Healthcare / health sciences (scope not detailed)

Aayush Worldwide Private Limited (CIN U46497MH2025PTC437587)

WOS

India (Maharashtra)

Jan 2025 (press release 7 Jan 2025; Directors' Report shows "Jan 04, 2024", likely a typographical error given the 2025 CIN year code)

Export of herbal and nutraceutical products

Aayush Labs Private Limited

WOS

India

26 Aug 2025

Diagnostics

Aayush Ventures Private Limited

WOS

India

27 Aug 2025

Investment / startup accelerator vehicle (inferred)

Aayush International Pte. Ltd.

WOS

Singapore

26 Sep 2025

ASEAN regional base; initial capital SGD 10,000

Income Statement and Margin Analysis (%)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

17.378.100.6073.39155.48

Total expenses (ex-dep, interest)

19.308.910.2570.10153.65

Operating profit / EBITDA

-1.93-0.810.353.441.83

Other income

——0.240.022.60

Interest expense

——0.000.100.00

Depreciation

——0.000.000.04

Profit before tax

——0.593.384.39

Tax rate (%)

——3.390.0010.00

Net profit (PAT)

——0.573.373.98

EPS basic (INR, split/bonus adjusted)

——0.120.690.82

Dividend per share (INR)

0000.010.025

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

————3.2

EBITDA / operating margin

-11.1-10.058.34.71.2

PBT margin

——98.34.62.8

Net margin

——95.04.62.6

Other income as % of PBT

——40.70.659.2

Growth metric (%)

Growth metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth YoY

-88.5-53.4-92.612,132111.9

PAT growth YoY

———49118.1

Income Statement and Margin Analysis (%) (Quarterly)

Metric (INR Cr)Q1FY2025Q2FY2025Q3FY2025Q4FY2025Q1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Sales

11.0814.2825.6322.3522.6339.9144.5348.4133.11

Operating profit

0.240.921.091.190.510.560.410.350.77

OPM (%)

2.176.444.255.322.251.400.920.722.33

Other income

0.020.000.000.020.650.650.650.650.65

PBT

0.260.921.091.111.151.201.050.991.41

Net profit

0.250.921.091.091.161.211.050.561.42

EPS (INR)

0.050.190.220.220.240.250.220.120.29

Balance Sheet

Metric (INR Cr)FY2024FY2025FY2026

Equity share capital

355

Reserves

237

Total equity

5812

Borrowings (total)

005

Other liabilities

001

Total liabilities and equity

5918

Fixed assets

000

Investments

000

Other assets (current)

5817

Goodwill and intangibles

000

Cash Flow and Margin Analysis (%)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Cash from operating activities

——-10-1

Cash from investing activities

——003

Cash from financing activities

——000

Net cash flow

——-102

Capex

——000

Free cash flow

——-10-1

Dividends paid

——000

Buybacks

00000

CFO / EBITDA (%)

——-16011-17

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025FY2026

ROE (%)

—38.838.8

ROCE (%)

—5135

ROA (%)

——28.2

ROIC (%)

——13.2

Debt / equity (x)

000.39

Interest coverage (x)

——277

Asset turnover (x)

0.128.28.6

Debtor days

1210

Inventory days

—12

Payable days

—11

Cash conversion cycle (days)

1211

Revenue by Region

Region (INR Cr)FY2024FY2025FY2026

Total revenue

0.6073.39155.48

Valuation Snapshot

MetricValueSource / date

Last close

₹25.30

Screener, 16 Oct 2026

1-year return

-57% (Screener); -62% to -71% (Anand Rathi, Aug–Sep 2026 snapshots)

Varies with look-back date

3-year price CAGR

125% (Screener); about 1,240–1,258% cumulative 3-year return (Anand Rathi)

Oct 2026 / Aug–Sep 2026

5-year price CAGR

68%

Screener

10-year price CAGR

34%

Screener

All-time high (split/bonus adjusted)

₹267.30 on 18 Jul 2025

Accord Fintech

Drawdown from ATH

About -90.5%

Computed

52-week range

₹21.20 – ₹66.90

Screener, Oct 2026

BSE group

X

Accord Fintech

Liquidity

BSE volume about 47,000–58,000 shares on sample days (2026)

Finology; MarketsMojo

Share Price

MetricJan2025Jun2025Jul2025Nov2025Mar2026Jun2026Oct2026

Share price (INR)

120.05136.95267.3035.8834.2528.7825.30

Valuation Multiples

MultipleAayush WellnessSource

P/E (TTM)

29.0x

Screener, Oct 2026

P/B

10.0x

Screener, Oct 2026 (Value Research 8.6x on 1 Oct 2026)

EV/EBITDA

26.2x

MarketInOut, Jul 2026

EV/Sales

0.75x

MarketInOut, Jul 2026

Market cap / sales

About 0.74x

Computed (₹123 crore / ₹166 crore)

Dividend yield

0.10%

Screener

Valuation Multiples (Annual)

MultipleJan2025Mar2026Oct2026

P/E (x)

99.981.329.0

P/B (x)

11.633.010.0

Dividend History

Fiscal yearDividend per share (INR)TypePayout (%)

FY2025

0.01

Interim (first ever)

1

FY2026

0.025

Per FY2025 Directors' Report; timing to be confirmed

3

Action by Date

DateAction

19 Jun 2024

10-for-1 split (FV ₹10 → ₹1)

29 Oct 2024

1:2 bonus (1 bonus share per 2 held)

2024 / Jan 2026

ESOP 2024 instituted; first grants approved 7 Jan 2026

Dec 2024 (reported)

Rights issue proposal; not completed

Analyst Conclusions

Management guidance

None issued. The FY2026 results press release (Jun 2026) set out qualitative intent: continued expansion across preventive healthcare, nutraceuticals, wellness supplements and digital health ecosystems. It gave no numerical targets.

Consensus expectations

Not available (no coverage). Simple run-rate arithmetic: Q1 FY2027 revenue of ₹33.1 crore annualises to about ₹132 crore, below FY2026's ₹155.5 crore. Matching FY2026 therefore requires a sequential rebound. TTM revenue at June 2026 was ₹166 crore.

Bull case

  1. Distribution flywheel. Blinkit plus marketplaces plus exports have doubled revenue for two years running (FY2025 to FY2026 +112%; Q1 FY2027 +46% YoY). With nine SKUs, a pivot toward higher-margin branded retail could lift OPM toward 5%+. Q1 FY2027 OPM already recovered to 2.3% from 0.7% in Q4 FY2026.

  2. International subsidiaries scaling. Subsidiary revenue rose from nil to about ₹8.4 crore in Q1 FY2027 at a positive margin. A Singapore hub could make exports a meaningful, possibly higher-margin, leg.

  3. Optionality at a low valuation in absolute terms. At about ₹123 crore market cap and about 0.75x EV/Sales, the market assigns little value to the healthcare-services options (Aayush Labs, kiosks via Healthrashi). Any visible, funded roll-out could re-rate the shares.

Bear case

  1. Revenue quality is questionable. A gross margin of about 3%, near-zero receivable and inventory days, and negative operating cash flow look like pass-through trading, not a consumer-health franchise. Reported "growth" may carry little economic value.

  2. Governance red flags are cumulative. No promoter, a cluster of LLPs selling down, two auditor exits in six months, a Beneish M-score above the risk threshold, unexplained flat other income supplying about 59% of PBT, and a 56-session upper-circuit run followed by a roughly 90% collapse. These match patterns that SEBI and the exchanges have historically scrutinised in micro-caps.

  3. Ambition-capital mismatch. Stated initiatives (₹25 crore kiosks, diagnostics, tourism, accelerator) far exceed a net worth of about ₹12 crore and negative free cash flow. The depressed share price and abandoned rights issue limit funding, so execution risk and dilution risk are both high.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Q2 FY2027 results (due by mid-Nov 2026)Tests whether the Q1 sequential decline was temporary; OPM trajectory
Disclosure of the source of other income (₹0.65 crore per quarter)Earnings-quality clarity
FY2026 Annual Report: auditor's report, CARO, related-party transactions, KMP remuneration, contingent liabilitiesKey governance diligence; any qualification or emphasis-of-matter
Postal ballot results (Aug 2026) and AGM outcome (Sep 2026)Shareholder support for new auditor and directors
Standalone vs. consolidated revenue split each quarterWhether the parent's brand business is growing (only +9% YoY in Q1 FY2027)
Capex / kiosk deployment evidence in cash-flow statementsValidates the healthcare-services strategy
Funding actions (rights issue, preferential allotment, ESOP dilution)Dilution risk
Exchange surveillance (ASM/GSM) status and any SEBI/BSE actionsRegulatory risk
Changes in top-holder stakes (Skybridge Incap, Avance Ventures, V Cats)Continued distribution or stabilisation
Regulatory developments in nutraceutical claims and pan masalaCategory risk

Analyst verdict

Aayush Wellness Limited is the corporate successor to Aayush Food and Herbs Limited. Within three years it has turned a dormant rice-trading shell into a company reporting ₹155 crore of FY2026 revenue and consistent, if small, quarterly profits. Measured by the top line, the pivot looks dramatic: FY2025 revenue rose more than a hundredfold and FY2026 doubled again. A portfolio of Ayurvedic and nutraceutical SKUs, quick-commerce and export channels, and a Singapore subsidiary give the "integrated preventive-healthcare" story a surface coherence.

The underlying financial statements tell a less flattering story. Gross margin of about 3% and operating margin of about 1% are commodity-trading economics. Working-capital days near zero and negative operating cash flow point to pass-through volume rather than a consumer brand with pricing power. More than half of FY2026 pre-tax profit came from a perfectly flat, undisclosed other-income stream. Most of Q1 FY2027's growth came from newly formed subsidiaries rather than the parent's branded business, which grew only 9%.

Governance is the decisive weakness. There has been no promoter since December 2023. Ownership is concentrated in LLPs that have been net sellers to a fast-growing retail base. The company lost two statutory auditors within six months. The stock ran up through more than fifty consecutive upper circuits before collapsing about 90%. No institution owns the shares and no analyst covers them.

On balance, Aayush Wellness should be treated as a high-risk, speculative micro-cap whose reported growth has not yet been validated by margins, cash generation or governance quality. The healthcare-services narrative remains largely unfunded. A constructive stance would require four things: (i) clean FY2026 audit opinions, (ii) transparent disclosure of other income and related-party flows, (iii) sustained operating margins above 5% with positive operating cash flow, and (iv) institutional or credible strategic ownership. Until then, the burden of proof rests firmly with the company.


End of dossier. All figures in INR unless stated. "Not publicly disclosed" means the data point was not found in company filings or reliable secondary sources reviewed as of 18 October 2026. Third-party data (Screener/C-MOTS, S&P via Simply Wall St, MarketInOut, Value Research, Tijori) may differ from audited filings because of rounding, classification and update timing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / notesAgeFY compensation

Naveenakumar (Naveena Kumar) Kunjaru (DIN 07087891)

Managing Director & Chairman

MD since 12 Jun 2023; Chairman since 13 Jun 2023

Signs essentially all exchange filings and press releases; public face of the turnaround. Prior roles and education not disclosed in sources reviewed.

About 45 (Simply Wall St, 2025)

Not disclosed in sources reviewed (Simply Wall St: "no data")

Surajmal Jain

Chief Financial Officer

About 2024 onward (tenure about 1.2 years as of May 2025, Simply Wall St)

———

Sneha Khemka

Company Secretary & Compliance Officer

Appointed 2024–25 (under 1 year as of May 2025)

———

Akshay Vijay Nawale

Former CFO

Listed in FY2023 Annual Report

Departure date not disclosed

——

Urmi Haresh Shah

Former Company Secretary

Listed in FY2023 Annual Report

Departure date not disclosed

——

“—” = not publicly disclosed.

Board of Directors

NameCategoryAppointedNotes

Naveenakumar Kunjaru

Executive, MD & Chairman

Jun 2023

Combined Chair/MD role

Kashiram Jadhav (DIN 11640980)

Additional Non-Executive Non-Independent Director

31 Mar 2026

Regularisation sought via postal ballot (Jul–Aug 2026)

Second additional director (name not captured in sources reviewed)

Additional Non-Executive Non-Independent Director

31 Mar 2026

Regularisation sought via postal ballot

Independent directors (names not captured in sources reviewed)

Non-Executive Independent

Appointments of 30 May 2023 and 27 Jun 2023 noted in FY2023 AGM notice

Committee memberships not captured

Board & Management Changes

DateChangeContext

12–13 Jun 2023

N. Kunjaru appointed MD and Chairman

Coincides with exit of promoter group and business pivot

May–Jun 2023

Independent directors appointed

Board reconstitution

2023–2025

CFO change (Nawale → Jain); CS change (Shah → Khemka)

Not explained in sources

31 Mar 2026

Two non-independent non-executive additional directors

No stated rationale; regularised via postal ballot

Shareholding Pattern

Category (%)Mar2022Mar2023Mar2024Mar2025Mar2026

Promoter and promoter group

32.5227.900.000.000.00

FIIs

00000

DIIs / mutual funds

00000

Public (all non-institutional)

67.4872.10100.00100.00100.00

Number of shareholders

2,3992,3302,06918,65442,658

Major Shareholders

HolderMar 2025 %Latest disclosed %Source

Skybridge Incap Advisory LLP

19.47

16.89 (Mar 2026)

Tijori; MarketsMojo

Avance Ventures Private Limited

15.29

9.12 (Mar 2026)

Vogue Stock (BSE pattern); Tijori

V Cats Consultancy LLP

13.42

13.42 (Sep 2025; later not separately listed)

Tijori

Send Grid Consultancy LLP

—

4.62 (date per Simply Wall St)

Simply Wall St

Slesha Commercial Limited

—4.39

Simply Wall St

Moonlight Multitrade LLP

—4.35

Simply Wall St

Tvisha Corporate Advisors LLP

—4.12

Simply Wall St

Anju Shah

—3.29

Simply Wall St

Deepak Kharwad

—3.08

Simply Wall St

Sarvagay Textile LLP

—2.44

Simply Wall St

Competitive Landscape

Competitors by Segment

CategoryNamed competitorsRelative positioning

Ayurvedic / herbal OTC tablets and supplements

Dabur India, Himalaya Wellness (private), Patanjali Ayurved (private) / Patanjali Foods (listed), Zandu (Emami), Baidyanath (private), Charak (private)

Incumbents with national distribution, pharmacy reach and decades of brand equity; Aayush is sub-scale

Nutraceuticals / supplements (D2C, gummies)

HealthKart (MuscleBlaze/HK Vitals, private), Power Gummies (private), Kapiva (private), OZiva (Reckitt), Wellbeing Nutrition (private), Amway India, Herbalife India

Venture-funded D2C brands with heavy marketing spend; Aayush lacks comparable marketing budgets

Consumer wellness (listed)

Zydus Wellness (Q3 FY2026 net sales up 113.7%, partly acquisition-led, per Indian Pharma Post)

Large listed benchmark for wellness brands

Mouth freshener / herbal pan masala

Pass Pass (DS Group), Rajnigandha (tobacco-free pan masala, DS Group), Vimal / other regional brands

Dominated by large private groups; regulation-sensitive category

Diagnostics / preventive health services

Dr Lal PathLabs (launched "Sovaaka" wellness centre), Metropolis Healthcare, Thyrocare, Redcliffe Labs (private), Tata 1mg Labs

Aayush Labs is a startup-scale entrant with no disclosed footprint

Health kiosks / telemedicine

e-Sanjeevani (government), Practo, Tata 1mg, Apollo 24/7

Aayush has one disclosed centre

Peer Comparison FY2026

MetricAayush WellnessKaveri SeedGRM OverseasChaman Lal SetiaSarveshwar Foods

Market cap (INR Cr)

1173,6841,6131,396430

Revenue TTM (INR Cr)

1661,2791,8691,4781,402

Net profit (INR Cr)

4.24248.5078.36125.1233.01

Net margin (%)

2.5219.094.138.402.34

ROE (%)

37.0414.0514.2215.667.01

P/E (x)

27.614.821.111.213.0

P/B (x)

8.61.82.61.80.9

Competitor Detail

MetricAayush Wellness

Revenue FY2026 (INR Cr)

155.5

Revenue growth FY2026 (%)

112

EBITDA margin FY2026 (%)

1.2

R&D intensity (%)

Not disclosed (≈0)

Company Snapshot

$18M

Revenue

1984

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Rapid revenue scale-up. Consolidated revenue went from ₹0.60 crore (FY2024) to ₹73.39 crore (FY2025) to ₹155.48 crore (FY2026). TTM was ₹166 crore at June 2026 (Screener; company PR, Jun 2026).
  • Consistent profitability post-pivot. Nine consecutive profitable quarters from Q1 FY2025 to Q1 FY2027, with quarterly PAT of ₹0.25–1.42 crore (Screener).
  • Light balance sheet. Debt/equity is 0.39 and interest coverage 277x (MarketInOut, Jul 2026). Fixed-asset needs are negligible.
  • Distribution partnerships secured. Flipkart (2024), Blinkit (Nov 2025) and an export distributor (Cosmos Holdings, Dec 2024).
  • Breadth of portfolio. Nine branded SKUs launched across sleep, beauty, cognition, immunity, liver, metabolic, respiratory and bone health between Jun 2024 and Oct 2026 (BSE launch intimations).
  • Return ratios. Reported ROE of 38.8% and ROCE of 35% (FY2026, Screener). These are flattered by the small equity base and other income (see Weaknesses).

Weaknesses

  • Razor-thin margins. FY2026 OPM was 1.2%, down from 4.7% in FY2025. TTM gross margin is about 3% (Screener; Simply Wall St).
  • Earnings depend on other income. ₹2.60 crore of other income was about 59% of FY2026 PBT, with an unexplained flat ₹0.65 crore per quarter (Screener).
  • Negative operating cash flow. CFO was -₹1 crore in FY2026 and -₹1 crore in FY2024, with CFO/EBITDA of -17% in FY2026 (Screener).
  • No R&D, no patents, no manufacturing. Fixed assets are about nil and no R&D line is disclosed (Screener balance sheet; results).
  • Generic brand name. "Aayush" is phonetically identical to the AYUSH ministry acronym and shared by numerous third-party products (marketplace listings for "Ayush Kwath" from Zandu, Shuddhi and others).
  • Thin, unstable management and governance. No promoter, combined Chair/MD, changes of CFO and CS since 2023, and auditor resignations in Aug 2025 and Feb 2026 (BSE filings).

Opportunities

  • Nutraceutical market growth. About US$18 billion growing at more than 15% CAGR (company-cited); Aayush's share is negligible, so headroom is large.
  • Quick-commerce scaling. Blinkit's hyperlocal network gives fast urban reach without building a field force (Nov 2025 PR).
  • ASEAN exports. Singapore subsidiary plus Cosmos order; subsidiary revenue about ₹8.4 crore in Q1 FY2027 (derived from Q1 FY2027 standalone vs. consolidated).
  • Herbal pan masala in Maharashtra. Enforcement against illegal gutkha under MCOCA could shift some demand to legal herbal alternatives (company PR, 17 Jun 2026).
  • Preventive diagnostics and kiosks. Healthrashi-sourced kiosks and mobile clinics, if funded, could create recurring service revenue (Sep 2025).
  • Government telemedicine alignment. The Virar centre is modelled on e-Sanjeevani, which could open public-programme tie-ups (Apr 2025 PR).

Threats

  • Regulatory risk on claims and categories. FSSAI nutraceutical rules and AYUSH advertising scrutiny. Disease-specific products ("Dia Shield", "Liver Detox", "Lung Care") carry elevated claims risk.
  • Pan masala category risk. State bans and enforcement (e.g., Maharashtra's gutkha regime) can spill over to legal pan masala products and their distribution.
  • Competition from well-capitalised incumbents and D2C brands (Dabur, Himalaya, HealthKart, Kapiva, OZiva/Reckitt, Zydus Wellness).
  • Customer and channel concentration. A single export distributor (Cosmos) and single quick-commerce partner create dependency risk.
  • Capital-market sentiment. The stock is down about 90% from ₹267.30 (Jul 2025) to about ₹25 (Oct 2026), which constrains equity funding for the ₹25 crore kiosk plan.
  • Exchange surveillance. As a BSE Group X stock with a history of long upper-circuit streaks, it is exposed to ASM/GSM surveillance actions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
15 Apr 2025Announces entry into diagnostics using genome-testing technology; cites an Indian diagnostics market of US$25 billion by 2028New business-line ambition
26 Apr 2025First Aayush Health Centre and Smart Health ATM in Virar, MumbaiFirst physical healthcare asset
6 May 2025Stock hits 7th consecutive 2% upper circuitStart of a speculative run
30 May 2025FY2025 results: revenue ₹73.4 crore; PAT ₹3.37 crore; EPS ₹0.69First full year post-pivot
2 Jun 2025Stock locked at upper circuit at ₹136.95 after resultsMarket enthusiasm
10 Jun 2025Board approves Singapore WOS (SGD 10,000); stock at 52-week high of ₹151.05Internationalisation
Jun 2025₹25 crore investment plan for smart health kiosks and medical support centresCapex ambition about 2x net worth
11–12 Jun 2025Global newswire placements promoting Herbal Pan Masala and Virar centreInvestor-relations push
21 Jun 2025Announces foray into tele-consultation and diagnostic testingServices expansion
11–14 Jul 2025Launches Brain Fuel Capsules; 56th consecutive upper circuit at ₹247Product launch; extreme price momentum
18 Jul 2025All-time high of ₹267.30Market cap peak, roughly ₹1,300 crore
12 Aug 2025Q1 FY2026 results: revenue ₹22.63 crore; PAT ₹1.16 croreGrowth continues; margins compress
14 Aug 2025Statutory auditor Bakliwal & Co. resigns with immediate effectGovernance red flag
26–29 Aug 2025Incorporates Aayush Labs Pvt Ltd and Aayush Ventures Pvt LtdGroup expansion
3 Sep 2025Launches Aayush Labs diagnostics brandServices launch
22–23 Sep 2025Healthrashi Nextgen collaboration; upper circuits at ₹70.59 and ₹74.11Partnership
26 Sep / 4 Oct 2025Singapore subsidiary Aayush International Pte Ltd incorporated (disclosed 4 Oct)ASEAN base
13 Nov 2025Q2 FY2026 results: revenue ₹39.91 crore (+180% YoY); PAT ₹1.21 croreStrong revenue; OPM 1.4%
17 Nov 2025Blinkit partnership; stock falls about 5% to ₹35.88 on 18 NovChannel expansion; market unconvinced
8 Dec 2025Launches Immunity Booster Tablets; stock at 52-week low of ₹30.70 on that date, then upper circuitProduct launch
18–26 Dec 2025RoC Mumbai approves shift of registered office to Maharashtra; new CINDomicile change
7 Jan 2026First ESOP 2024 grants approvedEmployee incentives
12–13 Feb 2026Q3 FY2026 results: revenue ₹44.53 crore; PAT ₹1.05 crore (reported as down 5.5% YoY)Profit stagnation despite revenue growth
14 Feb 2026Second statutory auditor resignation within six monthsSerious governance red flag
31 Mar 2026Two additional non-independent directors appointedBoard change
24 Apr 2026Launches Liver Care / Liver Detox Tablets; stock +6.8% to about ₹38Product launch
8 May 2026Launches Aayush Dia Shield Tablets (metabolic health)Product launch
21 May 2026A. Raghavendra Rao & Associates appointed statutory auditorAuditor vacancy filled
29–31 May 2026FY2026 audited results: revenue ₹155.5 crore; Q4 PAT ₹0.56 crore (-49% YoY) on 43% tax rateAnnual doubling; weak Q4
2 Jun 2026Press release on FY2026 performance (+112% revenue growth)Investor communication
17 Jun 2026Press release linking Maharashtra MCOCA crackdown on illegal gutkha to a herbal masala opportunityRegulatory-tailwind narrative
14 Jul 2026Postal ballot notice: auditor appointment and regularisation of two directorsGovernance housekeeping
13 Aug 2026Q1 FY2027 results: revenue ₹33.11 crore (+46% YoY, -32% QoQ); PAT ₹1.42 crore (+22%)Growth driven by subsidiaries
17 Aug 2026Postal ballot e-voting closesResolutions decided (result not captured)
29–31 Aug 2026Launches Lung Care TabletsProduct launch
29 Sep 2026AGM held; outcome filed; scrutiniser's report 1 Oct 2026Annual governance event
14 Oct 2026Regulation 74(5) certificate for Q2 FY2027Routine compliance
16 Oct 2026Launches Aayush Calcium Vitamin TabletsProduct launch

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Consolidated revenue from operations rose from INR 226.3 Mn in 2026 to INR 331.1 Mn in 2027.
Aayush Wellness Limited — Revenue by Segment
Series (INR Mn)20262027
Consolidated revenue from operations226.3331.1
Standalone revenue from operations226.3247.2
Implied subsidiary revenue083.9
Consolidated PAT11.614.2
Standalone PAT11.612
Implied subsidiary PAT02.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.